Editorial Perspectives On Patient Recruitment

  1. Overcome The 6 Main Aversions To Clinical Trial Participation 2/20/2020

    Recruitment is a problem for most clinical trials, and there are many reasons patients are not more willing to participate. Many are not aware of trials, they have physicians who do not refer them, or they do not understand the need for trials.

  2. A Small Biotech's 3 Steps To Recruitment Success 2/18/2020

    Millendo Therapeutics has a pipeline of products addressing endocrine diseases. One of the company's trials, ZEPHYR, enrolled over 150 patients at 38 sites worldwide. Recruitment was nothing short of a success story. Millendo began recruiting patients for that study well after its main competitors yet was the first to meet its enrollment target.

  3. Technology Advancements Spur Adoption Of Virtual Trials 1/17/2020

    Patient recruitment and retention in clinical trials has long been an issue for pharma companies. This results in many trials being delayed and even canceled. One recent advancement that could help with both recruitment and retention is virtual (decentralized) trials.

  4. Pfizer Vaccine Trial Focuses On Pregnant Women 11/7/2019

    According to Dr. Judith Absalon, senior medical director in vaccines clinical research and development at Pfizer, vaccinating pregnant women goes back several decades. Still, we seem to be amid a new frontier in vaccine innovation. Pfizer is working on an investigational vaccine designed to protect unborn infants against GBS infection.

  5. Rafael Pharmaceuticals Is Starving Cancer Cells 10/31/2019

    While many other oncology companies are focused on the development of targeted immuno-oncology therapies, Rafael Pharmaceuticals is working on a cancer metabolism drug that has the potential to revolutionize cancer treatment. Its primary objective is to produce anti-cancer agents that have minimal toxic effects on normal cells and tissues.

  6. NeuBase Prepares To Face The Challenges Of A Rare Disease Trial 10/1/2019

    NeuBase is attempting to create a treatment for two rare diseases: Huntington’s disease and myotonic dystrophy. The company will face several challenges along the way, with the first being patient recruitment. Will young patients even want to know if they have the disease?

  7. Idera Pharmaceuticals – A Patient Recruitment Success Story 9/24/2019

    Every company conducting clinical trials knows recruitment is a challenge. Slow recruitment can delay the start of a trial and, in some cases, cause them to be cancelled altogether. This is one factor that makes Idera Pharmaceuticals different. The company is months ahead on its patient recruitment goals.

  8. Lupus Community Tackles Treatment & Clinical Trial Barriers 7/29/2019

    Few treatments have been approved for Lupus and the industry has seen many failed clinical trials. Variations in care worldwide, as well as poor overall access to care, has also hampered efforts to bring relief to patients. For those reasons, the international lupus community has come together to conduct a study aimed at identifying clinical and treatment barriers that must be overcome.

  9. The Cell Therapy Discovery About To Disrupt Clinical Trials 7/2/2019

    While pursuing hid PhD in chemical engineering at MIT, Armon Sharei developed an interest in novel cell therapies. That interest led him to a discovery that today is the foundation of SQZ Biotech, a cell-therapy company where he serves as CEO. Sharei discovered a new method of inserting materials into cells more effectively than anything that currently existed.

  10. 23andMe Wants To Solve The Patient Recruitment Problem 6/18/2019

    Developing cures for many diseases will require research into genetic data of the type 23andMe is collecting. The company is also collecting user information via voluntary surveys, asking users several questions every time they log on. The company now has, on average, over 350 data points (which 23andMe calls phenotypic information) on each customer. This information is helping the company match patients to trials.